The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies

This activity was originally presented live at Asembia's AXS25 Summit in Las Vegas, Nevada on April 28, 2025.

Program Description
Transthyretin amyloidosis (ATTR) is a disorder caused by the misfolding of transthyretin (TTR) proteins, leading to fibril deposits in organs and tissues, with cardiac, neurologic, or mixed phenotypes. This session will focus specifically on transthyretin amyloid cardiomyopathy (ATTR-CM), exploring its unique pathophysiology, characterized by the deposition of misfolded TTR proteins in cardiac tissue, and the differentiation of ATTR-CM from other forms of ATTR. Delays in recognizing ATTR-CM and initiating appropriate management can exacerbate symptoms, reduce quality of life, and increase unnecessary health care resource utilization. Advances in research have introduced disease-modifying therapies (DMTs) specifically for ATTR-CM, which can slow disease progression and improve survival. This session will examine current and emerging treatment strategies with a focus on recent clinical trial data and evolving management guidelines. Faculty will utilize case-based discussion to explore practical considerations for treatment selection, therapy monitoring, and addressing challenges in patient care. Pharmacists will gain actionable insights to support the multidisciplinary management of ATTR-CM, optimize therapy use, and improve outcomes for affected patients.

Target Audience: Managed care and specialty pharmacists

Type of Activity: Application
Release date: May 6, 2025
Expiration date: May 6, 2026
Learner level: Intermediate
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify the disease burden of transthyretin amyloidosis cardiomyopathy (ATTR-CM), considering factors such as health care utilization, misdiagnosis, and quality of life for patients
• Examine clinical recommendations for treatment of ATTR-CM, taking into account the mechanisms of action, administration, dosing, and potential adverse effects of current and emerging therapies
• Use clinical evidence for approved and investigational therapies for ATTR-CM in the development of patient-specific treatment plans
• Manage the impact of high health care utilization in ATTR-CM through strategies to optimize multidisciplinary interventions and patient access to therapy

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-127-H01-P. The activity is available for CE credit through May 6, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Sabrina Livezey, PharmD, CSP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Teva Medical Advisory Board

Stormi Gale, PharmD, BCPS, BCCP, FHFSA, has the following relevant financial relationships with commercial interests to disclose:

Consultant: American Regent

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta, and Rebecca Green.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms